Possible biomarkers for cancer immunotherapy in general are PD-L1, tumor mutation burden (TMB), microsatellite instability (MSI), specific gene mutation, immunogenic neo-antigen, and gut microbiome [151], and possible application of these biomarkers for immunotherapy in thyroid cancers should be explored in further studies. Here, CD274 is linked to cancer.